Withdrawn trial sought new hope for stubborn blood cancer
NCT ID NCT06068881
Summary
This study aimed to see how well and how safe the pill tazemetostat was for adults whose follicular lymphoma, a type of blood cancer, had come back or stopped responding to treatment. It specifically focused on people whose cancer did not have a certain genetic change called an 'EZH2 gain-of-function' mutation. The trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.